Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Costacurta

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Personalized Medicine|November 27, 2021
Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma TherapyMatteo Costacurta, Jackson He, Philip E Thompson, et al.
Haematologica|December 30, 2020
Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myelomaMatteo Costacurta, Stephin J Vervoort, Simon J Hogg, et al.
The FEBS Journal|July 8, 2024
Mapping the IMiD-dependent cereblon interactome using BioID-proximity labellingMatteo Costacurta, Jarrod J Sandow, Belinda Maher, et al.
Oncotarget|January 19, 2017
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathwaysSabrina Manni, Marilena Carrino, Martina Manzoni, et al.
Cancer Discovery|May 15, 2021
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell MemoryEmily J Lelliott, Isabella Y Kong, Magnus Zethoven, et al.
Cell|May 18, 2021
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancerStephin J Vervoort, Sarah A Welsh, Jennifer R Devlin, et al.
Molecular Cell|May 21, 2021
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibitionSimon J Hogg, Olga Motorna, Leonie A Cluse, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Personalized Medicine|November 27, 2021
Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma TherapyMatteo Costacurta, Jackson He, Philip E Thompson, et al.
Haematologica|December 30, 2020
Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myelomaMatteo Costacurta, Stephin J Vervoort, Simon J Hogg, et al.
The FEBS Journal|July 8, 2024
Mapping the IMiD-dependent cereblon interactome using BioID-proximity labellingMatteo Costacurta, Jarrod J Sandow, Belinda Maher, et al.
Oncotarget|January 19, 2017
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathwaysSabrina Manni, Marilena Carrino, Martina Manzoni, et al.
Cancer Discovery|May 15, 2021
CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell MemoryEmily J Lelliott, Isabella Y Kong, Magnus Zethoven, et al.
Cell|May 18, 2021
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancerStephin J Vervoort, Sarah A Welsh, Jennifer R Devlin, et al.
Molecular Cell|May 21, 2021
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibitionSimon J Hogg, Olga Motorna, Leonie A Cluse, et al.
Pageof 1